MarketVIEW: Human metapneumovirus vaccines (CAT: VAMV062)

Product Name : MarketVIEW: Human metapneumovirus vaccines
Description : Global vaccine commercial opportunity assessment
Contents : Executive presentation (.pdf) + 1 forecast model (.xls)
Therapeutic Area : Novel vaccines
Publication date : June 2015
Catalogue No : VAMV062

Background

Human metapneumovirus (hMPV) is a member of the Metapneumovirus genus in the Pneumovirinae subfamily of the Paramyxoviridae family. The virus is transmitted between humans via direct or close contact and has a seasonality of infection similar to influenza and RSV. hMPV is the second most common cause of lower respiratory tract infections after RSV in young children. Most common causes for hospitalisation with hMPV are bronchiolitis and pneumonia. Mortality from hMPV occurs in 3.4–6.6% of hospitalised adults.

Because of its similarity to RSV and significant global morbidity and mortality, hMPV can be considered an attractive target for a new preventative vaccine.

This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of hMPV monovalent vaccines and bivalent vaccines (with RSV) across the seven major markets until 2035. The model contains value ($ m) and volume (mio doses) predictions per vaccine type per with BASE/HIGH scenarios along with timeframe, pricing and penetration estimates for all target populations. The product also includes an in depth review of latest hMPV epidemiological trends, treatments/guidelines and latest developments in R&D. It discusses the pros and cons of pursuing a monovalent versus bivalent approach.

1 Live attenuated vaccines, subunit vaccines
**Methodology**

*VacZine Analytics* has closely monitored all significant source material pertaining to human metapneumovirus and related respiratory pathogens e.g. RSV. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by *VacZine Analytics* in the field of novel vaccines has also been utilised.

**PRODUCT CONTENTS:**

Published June 2015 (CAT No: VAMV062)

****This product is composed of one forecast model (.xls) and a summary presentation (.pdf)

Author’s note

Contents

Executive summary

Executive summary: monovalent or bivalent strategy?

Commercial model: key model outputs

- Human metapneumovirus vaccines: global forecast revenue per scenario (all, $m) to 2035
- Human metapneumovirus vaccines: global forecast volume per scenario (all, 000s doses) to 2035
- hMPV vaccines: Base scenario (monovalent) volume and value by segment to 2035
- hMPV vaccines: High scenario (bivalent) volume and value by segment to 2035
- hMPV vaccines: Base scenario (monovalent) volume and value by country to 2035
- hMPV vaccines: High scenario (bivalent) volume and value by country to 2035
- hMPV vaccines: country market share by volume and value in 2035
- hMPV vaccines: volume (000s) for the adult segment by group
- hMPV vaccines: value share for the adult segment by group

Commercial summary: hMPV monovalent vs bivalent vaccines

- Human metapneumovirus: Disease background and epidemiology
- Human metapneumovirus: the pathogen
- Geographical distribution of hMPV serotypes
- Transmission and seasonality of hMPV
- Diagnosis of hMPV
- Clinical presentation of hMPV
- Epidemiology of hMPV
- Morbidity and mortality associated with hMPV
- Risk factors for hMPV and severe hMPV
- Economic burden of hMPV
- hMPV and respiratory syncytial virus: comparison and coinfection
- hMPV and RSV: disease parameters comparison
- Risk factors for hMPV and RSV are similar
- RSV and hMPV: age and probability of infection
- Treatment strategies for hMPV
- hMPV: treatment strategies under development
- hMPV: treatment strategies under development (cont.)
- Vaccination against hMPV: rationale and approaches
- Unmet need for an hMPV vaccine and historical approaches
- Approaches to hMPV vaccination (1): inactivated vaccines
Continued............

Approaches to hMPV vaccination (1): inactivated vaccines (cont.)
Approaches to hMPV vaccination (2): live attenuated vaccines (LAVs)
Approaches to hMPV vaccination (3): subunit vaccines
Approaches to hMPV vaccination (4): virus-like particle (VLP) vaccines and recombinant BCG vaccines
Approaches to hMPV vaccination (5): epitope vaccines
Key factors in hMPV vaccine development
hMPV vaccines in development: Overview of current R&D
Chimeric rhMPV-Pa (NIAID)
ViroNovative
Vanderbilt University
hMPV vaccines: R&D pipeline
Possibility of creating multivalent hMPV and RSV (and PIV) vaccines
hMPV vaccines: Target product profiles
hMPV vaccines: monovalent vaccine target product profile (TPP)
hMPV vaccines: bivalent vaccine target product profile (TPP)
hMPV vaccines: modelling commercial potential
Modelling scenarios: Base (monovalent vaccine)
Modelling scenarios: High (bivalent vaccine)
Modelling scenarios: summary
Recommendation/reimbursement
Pricing: infant immunisation (monovalent, Base model)
Pricing: adult immunisation (monovalent, Base model)
Pricing: bivalent vaccine (High model)
Methodology: populations
Methodology: coverage
Modelling: summary of start/peak coverage rates (US)
Model limitations and caveats
Influenza immunisation rates amongst eligible people in the 5EU countries54
RSV vaccine development pipeline (PATH)
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~75 slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model TX vaccine (MS Excel-based)

Title sheet
Scenario definitions
CHARTS (summary)
CHARTS (countries)
CHARTS (adult segments)
Value summary (base)
Volume summary (base)
Value summary (high)
Volume summary (high)
Continued............

Pricing summary
Base scenario
Country volume worksheets
US (base)
Canada (base)
France (base)
Germany (base)
Italy (base)
Spain (base)
UK (base)
Country populations
US
Canada
France
Germany
Italy
Spain
UK
Source material
Births
18yrs+ population
65yrs+ population
Total population
Asthma COPD epidemiology
CHF epidemiology
Coverage (COPD and HF)
Back page
About VacZine Analytics
Disclaimer

Worksheets ~ 44 interconnected
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $8995.00/ GBP £5800.00* (Region license)*
- PRESENTATION OR MODEL ONLY - USD $4995 (Region license)*

* Indicative rate only. Prevailing rate applied to date of transaction.
* A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009